Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Continuing evidence discrediting Sept's short article pozi pricing. Pfizer Xalkori follow-up Lorbrena for ALT mutations was just approved

to treat ALK-positive NSCLC after Xalkori and at least one other ALK inhibitor have failed, or as a second-line-treatment after Roche’s Alecensa or Novartis’ Zykadia.

Continuing from an article from Fierce Pharma

Xalkori is now vying in the previously untreated ALK-positive market with both Alecensa—which topped it in a head-to-head trial—and Zykadia. And soon, Takeda’s Alunbrig, which already boasts a second-line nod, could make its front-line debut; it posted positive data in untreated patients this July, following up with a big Xalkori head-to-head win in September. And Xalkori’s sales have retreated in response. In the first half of this year, its top-line contribution declined to $290 million from $296 million year over year.

It's being priced at $16,055 per month (i.e. $193,000 per year) amongst all this competition. Note that pozi won't have any competition and most likely will be priced higher. So when the short article by a Bob Shurma came out stating a $66,000 per yr price comparable to afatinib I had to laugh. But one needs to points these lies out or at least a severe lack of Due Diligence. A week later the $66,000 per year price was mentioned in an article by Avisol Capital Partners of which I just posted the Lorbrena pricing so they are aware you can't use an afatinib price of 5 yrs or so ago that was second TKI in that space at that time.

Edit - looks like it won't let me post a comment to the Avisol article. At least I got my original post published.